Screening system for identifying drug-drug interactions and methods of use thereof
    13.
    发明申请
    Screening system for identifying drug-drug interactions and methods of use thereof 审中-公开
    用于鉴定药物 - 药物相互作用的筛选系统及其使用方法

    公开(公告)号:US20080194421A1

    公开(公告)日:2008-08-14

    申请号:US12011051

    申请日:2008-01-24

    IPC分类号: C40B30/06 C40B30/00

    摘要: The invention features a method of screening for drug-drug interactions using combinational arrays. The method includes the steps of: (a) receiving a test drug from a client; (b) contacting the test drug and at least 200 library drugs from a drug library in an assay under conditions that ensure that each test drug/library drug contacting is segregated from the others; (c) recording the result of the contacting step (b); (d) identifying combinations of drugs that produce a result in the assay that is different from the results produced by either drug of the combination by itself, wherein each identified combination indicates an interaction between the test drug and the library drug of the combination; and (e) communicating the results of the identifying step (d) to the client.

    摘要翻译: 本发明的特征在于使用组合阵列筛选药物 - 药物相互作用的方法。 该方法包括以下步骤:(a)从客户端接收测试药物; (b)在确保每个测试药物/文库药物接触与其他药物分离的条件下,在测定中使测试药物和至少200种文库药物与药物文库接触; (c)记录接触步骤(b)的结果; (d)鉴定在测定中产生与本组合的任一药物产生的结果不同的药物组合,其中每个鉴定的组合表示该组合的测试药物与该文库药物之间的相互作用; 和(e)将识别步骤(d)的结果传达给客户。

    SMA Therapy and Cell Based Assay
    17.
    发明申请
    SMA Therapy and Cell Based Assay 审中-公开
    SMA治疗和基于细胞的测定

    公开(公告)号:US20090031435A1

    公开(公告)日:2009-01-29

    申请号:US11947589

    申请日:2007-11-29

    摘要: This invention relates to therapies for diseases involving splicing defects, such as spinal muscular atrophy (SMA), and methods to identify compounds for treating this disease. The invention specifically provides for therapies comprised of small molecule compounds identified by cell-based high-throughput screening assays. These assays utilize engineered splicing constructs that fuse pre-mRNA fragments to a reporter gene. The fragments contain exons and at least one intron of a gene mutated in such a way to cause disease. Additionally, the invention provides for methods to monitor the effects of drugs on splicing and gene expression in vivo, in transgenic animals.

    摘要翻译: 本发明涉及涉及拼接缺陷的疾病如脊髓性肌萎缩(SMA)的治疗方法,以及用于鉴定用于治疗该疾病的化合物的方法。 本发明特别提供由通过基于细胞的高通量筛选测定鉴定的小分子化合物组成的治疗。 这些测定利用将mRNA前体片段融合到报告基因的工程剪接构建体。 片段含有外显子和突变的基因的至少一个内含子,以引起疾病。 此外,本发明提供了在转基因动物中监测药物对体内剪接和基因表达的影响的方法。

    ASSAYS FOR NON-APOPTOTIC CELL DEATH AND USES THEREOF
    20.
    发明申请
    ASSAYS FOR NON-APOPTOTIC CELL DEATH AND USES THEREOF 失效
    非光照细胞死亡测定及其用途

    公开(公告)号:US20110008803A1

    公开(公告)日:2011-01-13

    申请号:US12308593

    申请日:2007-06-19

    IPC分类号: G01N33/574

    摘要: The invention relates to methods for identifying agents, which induce oxidative cell death in a tumor cell. The invention further relates to methods for identifying tumor cells, which are sensitive to agents that induce oxidative cell death. The invention also relates to methods for identifying subjects who are suffering from tumors, which are sensitive to agents that induce oxidative cell death.

    摘要翻译: 本发明涉及用于鉴定诱导肿瘤细胞中的氧化性细胞死亡的药剂的方法。 本发明还涉及用于鉴定对诱导氧化性细胞死亡的药物敏感的肿瘤细胞的方法。 本发明还涉及用于识别患有肿瘤的受试者的方法,其对诱导氧化性细胞死亡的药物敏感。